The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report

• Published in: Frontiers in oncology 2021-04, Vol.11, p.585983
• Main Authors: Huang, Xiaozhun, Wang, Chunling, Ma, Teng, Huang, Zhangkan, Zhou, Houhong, Xu, Lin, Zhang, Renjie, Zhao, Jianjun, Zhang, Yefan, Huang, Zhen, Shao, Lin, Wang, Yang, Yang, Fan, Che, Xu
• Format: Article
• Language: English
• Subjects: BRCA2 mutation; cisplatin; nanoparticle albumin-bound paclitaxel; Oncology; overall survival; pancreatic squamous cell carcinoma
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.585983

Pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage IV primary SCC of the pancreas harboring a deleteous somatic mutation. After 10 cycles of chemotherapy of cisplatin combined with nanoparticle albumin-bound paclitaxel, metastatic lesions in the liver and lymph nodes achieved radiographic complete responses and pancreatic lesion shrank from 5.7 to 1.5 cm in diameter. The patient subsequently underwent a posterior radical antegrade modular pancreatosplenectomy with R0 resection and residual liver lesions were also resected. After 3 months, a tumor relapsed in the liver. She was then treated with olaparib combined with pembrolizumab and achieved stable disease on the liver lesion. The patient eventually died from cerebral hemorrhage with a long OS of 21 months. Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with -mutant pancreatic SCC.